Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity Study in Healthy Subjects (abatacept)
A Randomized , Open Label, Three Arm, Parallel Group, Single Dose, Comparative Pharmacokinetic , Safety, and Immunogenicity Study Comparing KSHB002 (Abatacept) 125 mg/ ml Pre-filled Injection With US-Licenced ORENCIA and EU-Approved ORENCIA Administered Through Subcutaneous Route in Healthy Adult Human Volunteers
Sponsor: Kashiv BioSciences, LLC
Listed as NCT06929039, this PHASE1 trial focuses on Rheumatoid Arthritis (RA and remains completed. Sponsored by Kashiv BioSciences, LLC, it has been updated 1 time since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recordedEligibility Summary
No eligibility information available.
Contact Information
- Kashiv BioSciences, LLC
For direct contact, visit the study record on ClinicalTrials.gov .